Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombin III concentrates.

D Menache1

  • 1Plasma Derivatives Medical Services, American Red Cross National Headquarters, Washington, DC.

Hematology/Oncology Clinics of North America
|October 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coagulation factor IX concentrate: historical perspective.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2.

Haemophilia : the official journal of the World Federation of Hemophilia·1999
Same author

New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates.

Thrombosis and haemostasis·1997
Same author

Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups.

British journal of haematology·1996
Same author

Creutzfeldt-Jakob disease: current U.S. policy to further reduce the possible risk of transmission by transfusion.

Biologicals : journal of the International Association of Biological Standardization·1996
Same author

Safety monitoring and epidemiological surveillance of blood transfusion in the United States.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·1995
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Antithrombin III (AT III) concentrates are available in the US for preventing and treating blood clots in patients with AT III deficiency. Their use in both hereditary and acquired deficiency conditions is reported.

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • Antithrombin III (AT III) is a critical protein in regulating blood coagulation.
  • Deficiency in AT III increases the risk of thrombotic events.
  • Various AT III concentrates are available for therapeutic use.

Purpose of the Study:

  • To describe the characteristics of available antithrombin III concentrates in the United States.
  • To summarize the efficacy of AT III concentrates in managing thrombotic episodes in hereditary AT III deficiency.
  • To report on the application of AT III concentrates in acquired AT III deficiency states.

Main Methods:

  • Review of available antithrombin III concentrate products in the US market.
  • Summary of clinical data on the effectiveness of AT III concentrates.

Related Experiment Videos

  • Analysis of case reports and studies on acquired AT III deficiency.

    • Main Results:

    • General characteristics of US-available AT III concentrates are detailed.
    • Evidence supports the effectiveness of AT III concentrates in preventing and treating thrombosis in hereditary AT III deficiency.
    • Clinical use in acquired AT III deficiency conditions is documented.

    Conclusions:

    • Antithrombin III concentrates are valuable therapeutic agents for patients with AT III deficiency.
    • These concentrates play a role in both hereditary and acquired deficiency states.
    • Further research may elucidate optimal use in complex thrombotic conditions.